1.17
price up icon0.86%   0.01
after-market Handel nachbörslich: 1.19 0.02 +1.71%
loading
Schlusskurs vom Vortag:
$1.16
Offen:
$1.19
24-Stunden-Volumen:
3.79M
Relative Volume:
0.71
Marktkapitalisierung:
$354.30M
Einnahmen:
$95,000
Nettoeinkommen (Verlust:
$-327.27M
KGV:
-0.5519
EPS:
-2.12
Netto-Cashflow:
$-239.25M
1W Leistung:
-27.78%
1M Leistung:
-19.31%
6M Leistung:
-58.80%
1J Leistung:
-57.61%
1-Tages-Spanne:
Value
$1.16
$1.27
1-Wochen-Bereich:
Value
$1.09
$1.591
52-Wochen-Spanne:
Value
$1.09
$3.78

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
Firmenname
Allogene Therapeutics Inc
Name
Telefon
(650) 457-2700
Name
Adresse
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Mitarbeiter
361
Name
Twitter
@AllogeneTx
Name
Nächster Verdiensttermin
2025-05-02
Name
Neueste SEC-Einreichungen
Name
ALLO's Discussions on Twitter

Vergleichen Sie ALLO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.17 354.30M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
439.37 128.45B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
575.63 65.17B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
560.90 40.09B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.19 35.67B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
233.25 27.44B 3.81B -644.79M -669.77M -6.24

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-14 Hochstufung Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 Fortgesetzt Oppenheimer Outperform
2024-05-31 Eingeleitet Piper Sandler Overweight
2024-01-05 Herabstufung Guggenheim Buy → Neutral
2024-01-05 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 Eingeleitet Citigroup Buy
2023-06-26 Fortgesetzt Oppenheimer Outperform
2023-03-21 Eingeleitet Bernstein Mkt Perform
2023-01-24 Hochstufung JP Morgan Neutral → Overweight
2023-01-06 Hochstufung Robert W. Baird Neutral → Outperform
2022-12-12 Herabstufung BofA Securities Buy → Underperform
2022-08-10 Herabstufung Raymond James Outperform → Mkt Perform
2022-07-15 Hochstufung Goldman Neutral → Buy
2022-06-03 Eingeleitet Robert W. Baird Neutral
2022-02-28 Bestätigt B. Riley Securities Buy
2021-10-20 Eingeleitet Cowen Outperform
2021-10-08 Herabstufung Goldman Buy → Neutral
2021-10-08 Herabstufung Stifel Buy → Hold
2021-09-23 Hochstufung Raymond James Mkt Perform → Outperform
2021-06-21 Fortgesetzt Jefferies Buy
2021-05-20 Hochstufung Truist Hold → Buy
2021-05-14 Eingeleitet B. Riley Securities Buy
2021-01-26 Hochstufung Stifel Hold → Buy
2020-12-10 Fortgesetzt H.C. Wainwright Buy
2020-11-24 Eingeleitet BofA Securities Buy
2020-10-23 Eingeleitet RBC Capital Mkts Outperform
2020-06-01 Herabstufung Raymond James Outperform → Mkt Perform
2020-05-29 Bestätigt H.C. Wainwright Buy
2020-05-19 Hochstufung ROTH Capital Neutral → Buy
2020-05-15 Hochstufung Guggenheim Neutral → Buy
2020-05-14 Bestätigt H.C. Wainwright Buy
2020-05-14 Herabstufung SunTrust Buy → Hold
2020-04-13 Eingeleitet SunTrust Buy
2020-03-13 Eingeleitet H.C. Wainwright Buy
2020-03-05 Eingeleitet Stifel Hold
2020-02-24 Eingeleitet Berenberg Hold
2019-12-18 Eingeleitet JMP Securities Mkt Outperform
2019-11-04 Eingeleitet Canaccord Genuity Buy
2019-08-09 Eingeleitet BTIG Research Buy
2019-06-05 Eingeleitet ROTH Capital Neutral
2019-05-31 Eingeleitet Guggenheim Neutral
2019-05-23 Eingeleitet Stifel Hold
2019-03-29 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten

pulisher
08:54 AM

Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus

08:54 AM
pulisher
May 09, 2025

Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey

May 09, 2025
pulisher
May 07, 2025

Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) latest 17% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st

May 07, 2025
pulisher
May 06, 2025

Allogene Therapeutics to Report First Quarter 2025 Financial Res - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - The Manila Times

May 06, 2025
pulisher
Apr 25, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst institutional investors who own 59% - Yahoo Finance

Apr 25, 2025
pulisher
Apr 23, 2025

Allogene Therapeutics (ALLO) to Present New Findings on ALLO-316 and ALPHA3 Trials | ALLO Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Allogene Therapeutics to Present Updated ALLO-316 Clinical Resul - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Allogene Therapeutics to Present Updated Data on ALLO-316 and ALPHA3 Trials at 2025 ASCO Annual Meeting - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

First Allogeneic CAR T Shows Promise in Solid Tumors: Latest Clinical Data from Dual Cancer Trials at ASCO - Stock Titan

Apr 23, 2025
pulisher
Apr 10, 2025

Allogene received FDA Fast-track statuses for its dual CAR-Therapy - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline - Investing.com Australia

Apr 10, 2025
pulisher
Apr 09, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 08, 2025

FDA Grants Three Fast Track Tags To Allogene's Autoimmune Disease Drug - Barchart.com

Apr 08, 2025
pulisher
Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene Therapeutics’ ALLO-329 Snags FDA Fast Track Designations for 3 Rheumatology Indications - CGTLive®

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene's ALLO-329 Granted Three FDA Fast Track Designations - Nasdaq

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene Gets FDA Fast Track Designations for ALLO-329 in Autoimmune Diseases - marketscreener.com

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) For Allo-329 - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - The Manila Times

Apr 07, 2025
pulisher
Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Groundbreaking Triple FDA Fast Track: Allogene's New CAR T Targets Multiple Autoimmune Diseases - Stock Titan

Apr 07, 2025
pulisher
Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com India

Mar 19, 2025
pulisher
Mar 18, 2025

Allogene Therapeutics CEO sells $91,469 in stock - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Allogene Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Renal Cancer Clinical Pipeline | 75+ Companies, Including - openPR.com

Mar 18, 2025
pulisher
Mar 17, 2025

7th Annual Allogeneic Cell Therapies Summit - pharmaphorum

Mar 17, 2025
pulisher
Mar 17, 2025

Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech

Mar 17, 2025
pulisher
Mar 16, 2025

Allogene upgraded at Citizens after Q4 update - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 15, 2025
pulisher
Mar 15, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 15, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... By GuruFocus - Investing.com Canada

Mar 14, 2025

Finanzdaten der Allogene Therapeutics Inc-Aktie (ALLO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.75
price up icon 4.10%
$19.93
price up icon 2.94%
$33.35
price up icon 0.60%
$25.26
price up icon 5.43%
$97.27
price up icon 4.85%
biotechnology ONC
$233.25
price up icon 0.54%
Kapitalisierung:     |  Volumen (24h):